 Wave Life Sciences Ltd NASDAQ: WVE has announced the first proof-of-concept preclinical data for its ADAR adenosine deaminases acting on RNA-mediated RNA editing program in alpha-1 antitrypsin deficiency AATD. AATD is a genetic disorder that may result in lung disease or liver disease. 